Lord, Abbett & Co
ATYR

Lord, Abbett & Co’s aTyr Pharma ATYR Stock Holding History

Lord, Abbett & Co’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,747
Closed -$1.07M – 959
2015
Q4 		$1.07M Sell
7,747
-4,878
-39% -$694K ﹤0.01% 860
2015
Q3 		$1.81M Sell
12,625
-4,761
-27% -$1.09M 0.01% 854
2015
Q2 		$4.51M Buy
+17,386
New +$5.4M 0.01% 792

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Lord, Abbett & Co's ATYR Position: Q1 2016 in Review

Lord, Abbett & Co sold out of aTyr Pharma (ATYR) in Q1 2016, closing a stake of 7,747 shares — an estimated $1.07M sold.

Lord, Abbett & Co first reported a position in ATYR in Q2 2015 and held it in 3 quarters. The position peaked at $4.51M in Q2 2015. 50 funds tracked by Wall St. Rank hold ATYR as of Q1 2016.

  • Lord, Abbett & Co reported no remaining aTyr Pharma position as of Q1 2016 after selling out during the quarter.
  • Lord, Abbett & Co sold 7,747 aTyr Pharma shares in Q1 2016, an estimated $1.07M.
  • Lord, Abbett & Co first reported a position in aTyr Pharma in Q2 2015 and held it in 3 quarters.
  • Lord, Abbett & Co's aTyr Pharma position peaked at $4.51M in Q2 2015.
  • 50 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2016.

Based on Lord, Abbett & Co's 13F filing for Q1 2016, filed 16 May 2016.